Inhibitory Effect of Piperlonguminine/Dihydropiperlonguminine on the Production of Amyloid β and APP in SK-N-SH Cells

10.4077/CJP.2009.AMH062

Hong-Shun Qi；Pei Liu；Su-Qin Gao；Zeng-Yan Diao；Ling-Ling Yang；Jun Xu；Xun Qu；En-Ji Han

Alzheimer disease ； amyloid precursor protein ； amyloid β ； β-secretase ； γ-secretase ； piperlonguminine ； dihydropiperlonguminine ； futokadsura stem

The Chinese Journal of Physiology

52卷3期（2009 / 06 / 01）

160 - 168

英文

The study was undertaken to explore whether piperlonguminine/dihydropiperlonguminine could inhibit the production of amyloidβ (Aβ) in human neuroblastoma cells (SK-N-SH) and to examine the underlying mechanism of this effect. Piperlonguminine/dihydropiperlonguminine components (1:0.8) were extracted from Futokadsura stem, and then used to treat SK-N-SH cells at three different concentrations: 3.13 μg/ml, 6.25 μg/ml and 12.50 μg/ml. Subsequently, the production of Aβ42 and Aβ40 were measured by Western blot analysis and enzyme linked immunosorbent assay (ELISA). On the other hand, the expressions of amyloid precursor protein (APP), Notch1 (Notch intracellular domain) and β-site amyloid precursor protein cleavage enzyme (BACE-1) were also examined by Western blot assay. The activities of β-secretase and γ-secretase were detected at the same time. Furthermore, Aβ42 level was detected by immunocytochemistry staining. We demonstrated that the treatment of piperlonguminine/dihydropiperlonguminine could significantly decrease the levels of APP, Aβ42 and Aβ40 peptide in SK-N-SH cells, despite the fact that the activities of β-secretase and γ-secretase were not affected significantly. These data suggest that piperlonguminine/dihydropiperlonguminine components could significantly inhibit the level of APP, Aβ42 and Aβ40 peptide without affecting the activity of β-secretase and γ-secretase in SK-N-SH cells.

1. Findeis, M.A.(2007).The role of amyloid β peptide 42 in Alzheimer's disease.Pharmacol. Ther.,116,266-286.
2. Forero, D.A.,Casadesus, G.,Perry, G.,Arboleda, H.(2006).Synaptic dysfunction and oxidative stress in Alzheimer's disease: emerging mechanisms.J. Cell Mol. Med.,10,796-805.
3. Goedet, M.,Spillantini, M.G.(2006).A century of Alzheimer's disease.Science,314,777-781.
4. Goldgaber, D.,Harris, H.W.,Hla, T.,Maciag, T.,Donnelly, R.J.,Jacobsen, J.S.,Vitek, M.P.,Gajdusek, D.C.(1989).Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells.Proc. Natl. Acad. Sci. USA,86,7606-7610.
5. Han, E.,Rajiv, J.(1998).Inhibition of β-amyloid precursor protein gene expression by haifengteng.J. Chinese Med.,23,691-693.
6. Han, E.J.,Hu, H.T.,He, X.Q.,Deng, X.M.,Lu, Y.,Zhou, H.T.(2004).Selective inhibition of haifengteng in gene expression of β-amyloid precursor protein.Chinese J. Clin. Rehabil.,8,2592-2593.
7. Hardy, J.(2003).The relationship between amyloid and tau.J. Mol. Neurosci.,20,203-206.
8. Hauptmann, S.,Scherping, I.,Drose, S.,Brandt, U.,Schulz, K.L.,Jendrach, M.,Leuner, K.,Eckert, A.,Muller, W.E.(2009).Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice.Neurobiol. Aging.
9. Iwashita, M.,Saito, M.,Yamguchi, Y.,Takagaki, R.,Nakahata, N.(2007).Inhibitory effect of ethanol extract of piper longum L. on rabbit platelet aggregation through antagonizing thromboxane A2 receptor.Biol. Pharm. Bull.,30,1221-1225.
10. Kamenetz, F.,Tomita, T.,Hsieh, H.,Seabrook, G.,Borchelt, D.,Iwatsubo, T.,Sisodia, S.,Malinow, R.(2003).APP processing and synaptic function.Neuron,37,925-937.
11. Koh, J.Y.,Yang, L.L.,Cotman, C.W.(1990).Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage.Brain Res.,533,315-320.
12. LaFerla, F.M.,Oddo, S.(2005).Alzheimer's disease: Aβ, tau and synaptic dysfunction.Trends Mol. Med.,11,170-176.
13. Lahiri, D.K.,Ge, Y.W.,Maloney, B.(2005).Characterization of the APP proximal promoter and 5'-untranslated regions: identification of cell type-specific domains and implications in APP gene expression and Alzheimer's disease.FASEB J.,19,653-655.
14. Leissring, M.A.,Murphy, M.P.,Mead, T.R.,Akbari, Y.,Sugarman, M.C.,Jannatipour, M.,Anliker, B.,Muller, U.,Saftig, P.,De Strooper, B.,Wolfe, M.S.,Golde, T.E.,LaFerla, F.M.(2002).A physiologic signaling role for the γ-secretase-derived intracellular fragment of APP.Proc. Natl. Acad. Sci. USA,99,4697-4702.
15. Licastro, F.,Porcellini, E.,Caruso, C.,Lio, D.,Corder, E.H.(2007).Genetic risk profiles for Alzheimer's disease: Integration of APOE genotype and variants that up-regulate inflammation.Neurobiol. Aging,28,1637-1643.
16. Matsui, T.,Ingelsson, M.,Fukumoto, H.,Ramasamy, K.,Kowa, H.,Frosch, M.P.,Irizarry, M.C.,Hyman, B.T.(2007).Expression of APP pathway mRNAs and proteins in Alzheimer's disease.Brain Res.,1161,116-123.
17. Mattson, M.P.(2004).Pathways towards and away from Alzheimer's disease.Nature,430,631-639.
18. Nowotny, P.,Bertelsen, S.,Hinrichs, A.L.,Kauwe, J.S.,Mayo, K.,Jacquart, S.,Morris, J.C.,Goate, A.(2007).Association studies between common variants in prolyl isomerase Pin1 and the risk for late-onset Alzheimer's disease.Neurosci. Lett.,419,15-17.
19. Paris, D.,Patel, N.,Quadros, A.,Linan, M.,Bakshi, P.,Ait-Ghezala, G.,Mullan, M.(2007).Inhibition of Aβ production by NF-κB inhibitors.Neurosci. Lett.,415,11-16.
20. Patterson, C.,Feightner, J.W.,Garcia, A.,Hsiung, G.Y.R.,MacKnight, C.,Sadovnick, A.D.(2008).Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease.Can. Med. Assoc. J.,178,548-556.
21. Pietrzik, C.,Behl, C.(2005).Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application.Int. J. Exp. Pathol.,86,173-185.
22. Reddy, P.H.,Beal, M.F.(2005).Are mitochondria critical in the pathogenesis of Alzheimer's disease?.Brain Res. Brain Res. Rev.,49,618-632.
23. Schliebs, R.,Heidel, K.,Apelt, J.,Gniezdzinska, M.,Kirazov, L.,Szutowicz, A.(2006).Interaction of interleukin-1β with muscarinic acetylcholine receptor-mediated signaling cascade in cholinergically differentiated SH-SY5Y cells.Brain Res.,1122,78-85.
24. Shoji, M.,Golde, T.E.,Ghiso, J.,Cheung, T.T.,Estus, S.,Shaffer, L.M.,Cai, X.D.,McKay, D.M.,Tintner, R.,Frangione, B.,Younkin, S.G.(1992).Production of the Alzheimer amyloid beta protein by normal proteolytic processing.Science,258,126-129.
25. Sisodia, S.S.,St George-Hyslop, P.H.(2002).γ-Secretase, Notch, Aβ and Alzheimer's disease: where do the presenilins fit in?.Nat. Rev. Neurosci.,3,281-290.
26. Weggen, S.,Eriksen, J.L.,Das, P.,Sagi, S.A.,Wang, R.,Pietrzik, C.U.,Findlay, K.A.,Smith, T.E.,Murphy, M.P.,Bulter, T.,Kang, D.E.,Marquez-Sterling, N.,Golde, T.E.,Koo, E.H.(2001).A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooygenase activity.Nature,414,212-216.
27. Weggen, S.,Rogers, M.,Eriksen, J.(2007).NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?.Trends Pharmacol. Sci.,28,536-543.
28. Wolfe, M.S.(2002).APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease.Int. Immunopharmacol.,2,1919-1929.
29. Xia, W.,Zeng, J.P.,Chen, L.B.,Jiang, A.L.,Xiang, L.,Xu, J.,Cui, X.,Han, E.J.(2007).Inhibition of β-amyloid precursor protein gene in SK-N-SH cells by piperlonguminine/dihydropiperlonguminine components separated from Chinese herbal medicine Futokadsura stem.Chinese J. Physiol.,50,157-163.
30. Zhu, X.,Smith, M.A.,Honda, K.,Aliev, G.,Moreira, P.I.,Nunomura, A.,Casadesus, G.,Harris, P.L.,Siedlak, S.L.,Perry, G.(2007).Vascular oxidative stress in Alzheimer disease.J. Neurol. Sci.,257,240-246.

1. Xiang, Lan,Xia, Zuo-Li,Xia, Wen,Li, Da-Wei,Han, En-Ji,Chang, Jun-Jing(2015).Neuroprotective Effects of an Aqueous Extract of Futokadsura Stem in an Aβ-Induced Alzheimer's Disease-Like Rat Model.中國生理學雜誌,58(2),104-113.